Landscape Capital Management L.L.C. Acquires 155,048 Shares of Elanco Animal Health Incorporated $ELAN

Landscape Capital Management L.L.C. lifted its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 106.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,930 shares of the company’s stock after buying an additional 155,048 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Elanco Animal Health were worth $6,061,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of ELAN. AlphaQuest LLC grew its holdings in Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock worth $120,000 after purchasing an additional 718 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after purchasing an additional 798 shares in the last quarter. MTM Investment Management LLC grew its stake in shares of Elanco Animal Health by 5.5% in the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after buying an additional 800 shares during the last quarter. US Bancorp DE grew its stake in shares of Elanco Animal Health by 1.9% in the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after buying an additional 824 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its position in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $0.11 during trading hours on Friday, hitting $22.79. 240,483 shares of the company’s stock traded hands, compared to its average volume of 4,483,958. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $27.72. The firm has a market capitalization of $11.33 billion, a P/E ratio of -47.48, a P/E/G ratio of 2.99 and a beta of 1.83. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The business’s fifty day moving average price is $24.51 and its two-hundred day moving average price is $22.15.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.14 EPS. The company’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ELAN shares. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. Barclays began coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. Morgan Stanley lifted their price target on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. KeyCorp upped their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.